GlassScriptPhysician profile
Krystal Dawn Limb
NPI 1952025579
$977.62
in general payments reported to CMS, 2019-2025
18 companies · $911 in 2025
The $911 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $66.93 · 2025: $911.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $962 · Education: $15.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $961.69 |
| Education | $15.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $366.37 | 2025 | Ozempic, Rybelsus, Wegovy |
| Kowa Pharmaceuticals America, INC. | $124.80 | 2025 | Zoryve |
| Astrazeneca Pharmaceuticals LP | $107.85 | 2025 | Breztri, Farxiga, Airsupra |
| Dexcom, INC. | $78.03 | 2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Lilly USA, LLC | $49.90 | 2023-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $31.05 | 2025 | Cologuard Collection Kit |
| Abbvie INC. | $28.33 | 2025 | |
| Glaxosmithkline, LLC. | $22.15 | 2025 | Trelegy Ellipta |
| Inspire Medical Systems, INC. | $21.20 | 2025 | Inspire |
| Sumitomo Pharma America, INC. | $21.01 | 2025 | Gemtesa |
| Axsome Therapeutics, INC. | $18.44 | 2025 | Auvelity |
| Acella Pharmaceuticals, LLC | $18.29 | 2025 | NP Thyroid 60 |
| Takeda Pharmaceuticals U.S.A., INC. | $15.93 | 2025 | |
| Antares Pharma, INC. | $15.16 | 2025 | Xyosted |
| Ironshore Pharmaceuticals INC. | $15.09 | 2023 | Jornay Pm |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.08 | 2023 | Xifaxan |
| Itamar Medical INC | $14.90 | 2023 | Watchpatone |
| Tolmar, INC. | $14.04 | 2025 | Jatenzo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krystal Limb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.